Antiviral Breakthrough

Paxlovid represents a significant advancement in COVID treatment, with a remarkable efficacy rate of 100% in preventing death among trial participants. This oral antiviral, taken over five days, aims to keep patients out of hospitals during surges, alleviating pressure on healthcare systems. The discussion also touches on the scrutiny surrounding alternative treatments, emphasizing the importance of reliable scientific evidence in the fight against COVID.